NCT03359876View on ClinicalTrials.gov

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

CompletedOBSERVATIONAL
Enrollment

16,000

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

March 29, 2019

Study Completion Date

March 29, 2019

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15 mg, once daily

DRUG

Warfarin sodium

Individually adjusted dose

Trial Locations (1)

07981

US Truven MarketScan, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY